Valeria R. Aguiar

Santo Andre, SP, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Spot size variation and skin interaction of long-pulse 1064nm Nd: YAG laser used for varicose veins treatment: A prospective, randomized, assessor-blinded ex vivo study.

Spot size variation and skin interaction of long-pulse 1064nm Nd: YAG laser used for varicose veins treatment: A prospective, randomized, assessor-blinded ex vivo study.

Journal: Phlebology

Published: August 20, 2026

Q-switched and ultra-short-pulse Nd:YAG 1064 nm laser treatment for stasis dermatitis secondary to chronic venous hypertension: Rationale and design of the SUPERSTAR trial.

Q-switched and ultra-short-pulse Nd:YAG 1064 nm laser treatment for stasis dermatitis secondary to chronic venous hypertension: Rationale and design of the SUPERSTAR trial.

Journal: Phlebology

Published: June 23, 2026

Pulsed Electromagnetic Field Therapy Compared to Conventional Mechanical Prophylaxis for Venous Thromboembolism Prophylaxis in The Intensive Care Unit - Rationale and Design for The SOPHIE Trial.

Pulsed Electromagnetic Field Therapy Compared to Conventional Mechanical Prophylaxis for Venous Thromboembolism Prophylaxis in The Intensive Care Unit - Rationale and Design for The SOPHIE Trial.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: November 18, 2025

Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent Claudication.

Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent Claudication.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: October 23, 2025

Rivaroxaban for Patients with Intermittent Claudication.

Rivaroxaban for Patients with Intermittent Claudication.

Journal: NEJM evidence

Published: August 26, 2024

Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial.

Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial.

Journal: Circulation

Published: July 01, 2024

Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).

Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).

Journal: Revista da Sociedade Brasileira de Medicina Tropical

Published: November 08, 2022

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial.

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: January 19, 2022

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.

Journal: Lancet (London, England)

Published: September 13, 2021

Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial.

Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial.

Journal: American heart journal

Published: May 06, 2021

Zika and Chikungunya Virus and Risk for Venous Thromboembolism.

Zika and Chikungunya Virus and Risk for Venous Thromboembolism.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: February 28, 2019

Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.

Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: November 30, 2018

Showing 1-12 of 13

Last Updated: 09/26/2026